Associate Professor of Oncology, Johns Hopkins University School of Medicine
Oncology
Dr. Ivan M. Borrello, MD
|
|
Give Review
Ivan Borrello practices Oncology. He attended Virginia Commonwealth University School of Medicine. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Ivan M. Borrello is also a published doctor. He has 62 paper published. The most recent paper is: Tolerance and cancer: a critical issue in tumor immunology. Ivan Borrello accepts Medicare.
Publications
- Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents.
- Risk-stratified outcomes of nonmyeloablative, HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.
- Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell Carcinoma.
- Tadalafil augments tumor specific immunity in patients with head and neck squamous cell Carcinoma.
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma.
- Post-transplantation cyclophosphamide as single-agent GVHD prophylaxis after myeloablative conditioning and HLA-matched allografting for Acute leukemias and myelodyspl...
- Activation of liver x receptors inhibits hedgehog signaling, clonogenic growth, and self-renewal in multiple Myeloma.
- Infusion of cryopreserved autologous lymphocytes using a standard Peripheral i.v. catheter.
- Autologous Mesenchymal Stem Cells Produce Concordant Improvements in Regional Function, Tissue Perfusion, and Fibrotic Burden When Administered to Patients Undergoing ...
- Targeting Immune Suppression with PDE5 Inhibition in End-Stage Multiple Myeloma.
- Growth Differentiating Factor 15 enhances the tumor initiating and self-renewal potential of multiple Myeloma cells.
- Absence of Post-Transplantation Lymphoproliferative Disorder after Allogeneic Blood or Marrow Transplantation Using Post-Transplantation Cyclophosphamide as Graft-vers...
- The immune microenvironment of Myeloma.
- Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with Chronic lymphocytic leukaemia: in vivo evidence of immune a...
- High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell Lymphomas.
- Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model.
- The bone marrow stroma in hematological neoplasms--a guilty bystander.
- Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple Myeloma.
- A novel role of IL-17-producing lymphocytes in mediating lytic bone Disease in multiple myeloma.
- Development of target-specific treatments in multiple Myeloma.
- High-dose cyclophosphamide as single-agent, short-course prophylaxis of Graft-versus-host disease.
- Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.
- Conflicts of interest, authorship, and disclosures in industry-related scientific publications.
- Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremis...
- Characteristics of bortezomib- and thalidomide-induced Peripheral neuropathy.
- Lenalidomide in renal insufficiency--balancing the risks and benefits.
- Myeloid-derived suppressor cells promote cross-tolerance in B-cell Lymphoma by expanding regulatory T cells.
- HLA-haploidentical bone marrow transplantation for hematologic Malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.
- Myeloablative allogeneic bone marrow transplant using T cell depleted alloGrafts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes.
- Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation.
- Clonogenic multiple Myeloma progenitors, stem cell properties, and drug resistance.
- Lenalidomide plus dexamethasone for relapsed multiple Myeloma in North America.
- Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk Lymphoma.
- Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing Myeloid-derived suppressor cell function.
- Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells.
- Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions.
- In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell Lymphomas leading to antitumor immunity.
- Myeloid suppressor cells in Cancer: recruitment, phenotype, properties, and mechanisms of immune suppression.
- Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors.
- High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of Myeloid suppressor cells.
- Immunotherapeutic approaches for hematologic Malignancies.
- Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to...
- Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem cells.
- Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple Myeloma: importance of allogeneic T cells.
- Successful therapy of metastatic Cancer using tumor vaccines in mixed allogeneic bone marrow chimeras.
- GM-CSF-based cellular vaccines: a review of the clinical experience.
- Cancer vaccines for hematologic malignancies.
- New Developments in the Therapy of Acute Myelocytic Leukemia.
- Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymph...
- New approaches to treating malignances with stem cell transplantation.
- Sustaining the Graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines.
- In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance.
- A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines.
- Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40.
- Tolerance and Cancer: a critical issue in tumor immunology.
- Induction of antigen-specific T cell anergy: An early event in the course of tumor progression.
- Demonstration of epidermal growth factor-induced receptor dimerization in living cells using a chemical covalent cross-linking agent.
- Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3.
- Ligand-independent tyrosine phosphorylation of EGF receptor and the erbB-2/neu proto-oncogene product is induced by hyperosmotic shock.
- The calcium signal for BALB/MK keratinocyte terminal differentiation counteracts epidermal growth factor (EGF) very early in the EGF-induced proliferative pathway.
- Autologous stem cell transplantation and multiple myeloma Cancer stem cells.
Schools
Virginia Commonwealth University Medical College Of Virginia School Of Medicine
University of Chicago
Johns Hopkins
Procedures Preformed
- Bone Marrow Transplant
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Bladder Cancer
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Johns Hopkins University -
University of Chicago -
Virginia Commonwealth University School of Medicine
Hospital
-
Johns Hopkins Hospital
Drug Facts
| NPI NUMBER | 1992761050 | |
| NPPES Provider LastName | BORRELLO | |
| NPPES Provider FirstName | IVAN | |
| NPPES Provider ZIPCode | 212630001 | |
| NPPES Provider State | MD | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 67.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 24.0 | |
| Percent Opioid Claims | 35.82 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1992761050 |
| Last Name Of The Provider | BORRELLO |
| First Name Of The Provider | IVAN |
| View All |
Similar Doctors
|
|
Dr. Enser W. Cole III, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ting Bao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arif Hussain, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles S. Hesdorffer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael A. Carducci, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Nilofer S. Azad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dung T. Le, MD |
|
|
Dr. Samuel Zygler, MD
This Doctor is OpenDoctor Recommended.
|